Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe
Cryoport (Nasdaq: CYRX) announced the opening of its new IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium. The ~1,300 square meter GMP-compliant cryopreservation facility can process over 1,100 leukapheresis products annually. The Center of Excellence will provide standardized bioprocessing, cryopreservation, and distribution solutions for cell therapy manufacturing, focusing on leukapheresis starting materials. The facility will serve as Cryoport Systems' European Center of Excellence, transferring optimized cryopreservation processes to other Cryoport facilities to ensure consistent quality across clinical and commercial cell-based therapy programs.
Cryoport (Nasdaq: CYRX) ha annunciato l'apertura della sua nuova struttura IntegriCell™ a Villers-le-Bouillet, Liegi, Belgio. La struttura per la crioconservazione, conforme alle normative GMP, si estende su una superficie di circa 1.300 metri quadrati e può elaborare oltre 1.100 prodotti di leucafereesi all'anno. Il Centro di Eccellenza fornirà soluzioni standardizzate per bioprocessing, crioconservazione e distribuzione per la produzione di terapie cellulari, concentrandosi sui materiali di partenza di leucafereesi. La struttura fungerà da Centro di Eccellenza europeo per Cryoport Systems, trasferendo processi di crioconservazione ottimizzati ad altre strutture Cryoport per garantire qualità costante nei programmi di terapia cellulare clinici e commerciali.
Cryoport (Nasdaq: CYRX) anunció la apertura de su nueva instalación IntegriCell™ en Villers-le-Bouillet, Lieja, Bélgica. La instalación de criopreservación, que cumple con las normas GMP, tiene aproximadamente 1.300 metros cuadrados y puede procesar más de 1.100 productos de leucaféresis anualmente. El Centro de Excelencia proporcionará soluciones estandarizadas para bio-procesamiento, criopreservación y distribución para la fabricación de terapias celulares, centrándose en los materiales iniciales de leucaféresis. La instalación servirá como el Centro de Excelencia europeo de Cryoport Systems, transfiriendo procesos de criopreservación optimizados a otras instalaciones de Cryoport para garantizar una calidad consistente en los programas de terapia celular clínicos y comerciales.
Cryoport (Nasdaq: CYRX)는 벨기에 리에주 비에르르 르 부이예에서 새 IntegriCell™ 시설의 개장을 발표했습니다. 약 1,300제곱미터 규모의 GMP 준수 냉동 보존 시설은 연간 1,100개 이상의 백혈구 채취 제품을 처리할 수 있습니다. 우수 센터는 백혈구 채취 원료에 중점을 두어 세포 치료제 제조를 위한 표준화된 생물공정, 냉동 보존 및 유통 솔루션을 제공합니다. 이 시설은 Cryoport Systems의 유럽 우수 센터로, 일관된 품질을 보장하기 위해 다른 Cryoport 시설에 최적화된 냉동 보존 프로세스를 전이할 것입니다.
Cryoport (Nasdaq: CYRX) a annoncé l'ouverture de sa nouvelle installation IntegriCell™ à Villers-le-Bouillet, Liège, Belgique. L'installation de cryoconservation conforme aux normes GMP s'étend sur environ 1 300 mètres carrés et peut traiter plus de 1 100 produits de leucaphérèse par an. Le Centre d'Excellence fournira des solutions standardisées de bioprocédés, de cryoconservation et de distribution pour la fabrication de thérapies cellulaires, en se concentrant sur les matériaux de départ de leucaphérèse. L'installation servira de Centre d'Excellence européen pour Cryoport Systems, transférant des processus de cryoconservation optimisés vers d'autres installations Cryoport afin d'assurer une qualité constante dans les programmes de thérapie cellulaire cliniques et commerciaux.
Cryoport (Nasdaq: CYRX) hat die Eröffnung seiner neuen IntegriCell™ Einrichtung in Villers-le-Bouillet, Lüttich, Belgien, bekannt gegeben. Die etwa 1.300 Quadratmeter große GMP-konforme Kryokonservierungsanlage kann über 1.100 Leukaphereseprodukte jährlich verarbeiten. Das Zentrum für Exzellenz wird standardisierte Bioprozessierung, Kryokonservierung und Vertriebs-lösungen für die Herstellung von Zelltherapien anbieten, mit dem Fokus auf Leukapherese-Startmaterialien. Die Einrichtung wird als Europäisches Zentrum für Exzellenz von Cryoport Systems dienen und optimierte Kryokonservierungsprozesse auf andere Cryoport-Einrichtungen übertragen, um eine konsistente Qualität in klinischen und kommerziellen zellbasierten Therapieprogrammen sicherzustellen.
- Expansion of operational capacity with new 13,400 sq. ft. GMP-compliant facility
- Annual processing capability of over 1,100 leukapheresis products
- Strategic expansion into European market
- Facility designed with room for future expansion
- None.
Insights
The opening of Cryoport's new IntegriCell facility in Belgium represents a strategic expansion in the cell therapy supply chain infrastructure. The 1,300 square meter GMP-compliant facility with an annual capacity of 1,100 leukapheresis products addresses a critical market need for standardized cryopreservation services in Europe.
The facility's focus on leukapheresis material preservation is particularly significant as cell therapy development accelerates globally. This expansion provides essential infrastructure for both clinical trials and commercial cell therapy programs, potentially reducing manufacturing bottlenecks and improving therapy accessibility. The standardization of cryopreservation processes across facilities could lead to more consistent product quality and improved scalability for cell therapy manufacturers.
This expansion strengthens Cryoport's competitive position in the rapidly growing cell therapy market. The European location is strategically important, as the region is experiencing significant growth in cell therapy development and commercialization. The facility's design allowing for future expansion indicates management's confidence in market growth and positions the company to capture increasing demand.
While the immediate revenue impact may be modest, this investment enhances Cryoport's long-term growth potential by expanding its service offering and geographical reach. The focus on standardization and quality control aligns with industry trends toward increased regulation and quality requirements in cell therapy manufacturing.
Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs
IntegriCell is a standardized bioprocessing, cryopreservation and distribution solution for the global cell therapy market. The solution is designed to enhance cell therapy manufacturing efficiency and flexibility, ensuring safety, quality and product stability to support the effective scale up, production and availability of these lifesaving treatments to an expanding number of patients.
This ~1,300 square meter (~13,400 sq. ft.), custom-built, GMP-compliant cryopreservation facility expands Cryoport's capabilities by developing, optimizing and validating cryogenic preservation methods for leukapheresis materials to meet the highest standards for cell-based therapies. The facility has the capacity to cryopreserve over 1,100 leukapheresis products annually. IntegriCell will provide a reliable supply of high-quality, manufacture-ready cryopreserved leukopaks. As Cryoport Systems' European Center of Excellence, the IntegriCell Belgium site will transfer these optimized cryopreservation processes to other Cryoport facilities, ensuring consistent quality across clinical and commercial cell-based therapy programs.
"Our new IntegriCell Belgium facility extends our global reach and strengthens our ability to deliver consistent, high-quality cryopreservation solutions for the cell therapy community," said Jerrell Shelton, CEO of Cryoport. "This Center of Excellence, together with our
Details on the IntegriCell Belgium facility grand opening event will be shared through Cryoport's social media channels in the upcoming weeks.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the IntegriCell solution to support the development and commercialization of cell and gene therapies, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-expands-integricell-cryopreservation-services-solution-with-opening-of-new-center-of-excellence-in-europe-302302519.html
SOURCE Cryoport, Inc.
FAQ
What is the capacity of Cryoport's new IntegriCell facility in Belgium?
Where is Cryoport's (CYRX) new European IntegriCell facility located?
What services will Cryoport's (CYRX) new IntegriCell facility provide?
